Literature DB >> 15449312

Transcriptional activities of mutant p53: when mutations are more than a loss.

Ella Kim1, Wolfgang Deppert.   

Abstract

The dominant oncogenic properties of mutant p53 have been recognized as a phenomenon associated with tumor progression a long time ago, even before it was realized that the major function of wild type p53 is that of a tumor suppressor. Recent advances in this fascinating area in tumor cell biology reveal that the community of mutant p53 proteins is comprised of proteins that are extremely diverse both structurally and functionally, and elicit a multitude of cellular responses that not only are entirely distinct from those mediated by wild type p53, but also vary among different mutant p53 proteins. Aberrant regulation of transcription is one of the mechanisms underlying the ability of some mutant p53 proteins to act as oncogenic factors. Systematic analyses of the transcriptional activities of mutant p53 suggest that not the loss of transcriptional activity as such, but alterations of target DNA selectivity may be the driving force of mutant p53 specific transcription underlying the growth-promoting effects of mutant p53. This article focuses on mechanistic aspects of mutp53 "gain-of-function" with the emphasis on possible mechanisms underlying transcriptional activation by mutp53. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15449312     DOI: 10.1002/jcb.20271

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  31 in total

1.  17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells.

Authors:  Jennifer M Napper; Vincent E Sollars
Journal:  Leuk Res       Date:  2010-06-19       Impact factor: 3.156

2.  Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.

Authors:  Richard J Jones; Chad C Bjorklund; Veerabhadran Baladandayuthapani; Deborah J Kuhn; Robert Z Orlowski
Journal:  Mol Cancer Ther       Date:  2012-08-28       Impact factor: 6.261

3.  Co-expression of p16 and p53 characterizes aggressive subtypes of ductal intraepithelial neoplasia.

Authors:  Charles Bechert; Jee-Yeon Kim; Trine Tramm; Fattaneh A Tavassoli
Journal:  Virchows Arch       Date:  2016-09-23       Impact factor: 4.064

4.  Mutant p53 promotes tumor cell malignancy by both positive and negative regulation of the transforming growth factor β (TGF-β) pathway.

Authors:  Lei Ji; Jinjin Xu; Jian Liu; Ali Amjad; Kun Zhang; Qingwu Liu; Lei Zhou; Jianru Xiao; Xiaotao Li
Journal:  J Biol Chem       Date:  2015-03-12       Impact factor: 5.157

5.  Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.

Authors:  Eyal Kalo; Yosef Buganim; Keren E Shapira; Hilla Besserglick; Naomi Goldfinger; Lilach Weisz; Perry Stambolsky; Yoav I Henis; Varda Rotter
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

Review 6.  Awakening guardian angels: drugging the p53 pathway.

Authors:  Christopher J Brown; Sonia Lain; Chandra S Verma; Alan R Fersht; David P Lane
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

Review 7.  When mutants gain new powers: news from the mutant p53 field.

Authors:  Ran Brosh; Varda Rotter
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

8.  The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

Authors:  Giulia Fontemaggi; Stefania Dell'Orso; Daniela Trisciuoglio; Tal Shay; Elisa Melucci; Francesco Fazi; Irene Terrenato; Marcella Mottolese; Paola Muti; Eytan Domany; Donatella Del Bufalo; Sabrina Strano; Giovanni Blandino
Journal:  Nat Struct Mol Biol       Date:  2009-09-27       Impact factor: 15.369

9.  Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences.

Authors:  Marie Brázdová; Timo Quante; Lars Tögel; Korden Walter; Christine Loscher; Vlastimil Tichý; Lenka Cincárová; Wolfgang Deppert; Genrich V Tolstonog
Journal:  Nucleic Acids Res       Date:  2009-01-12       Impact factor: 16.971

10.  Mutant p53 mediates survival of breast cancer cells.

Authors:  L Y Lim; N Vidnovic; L W Ellisen; C-O Leong
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.